Adeshwar Meditex Ltd reported a contraction in financials for FY 2025-26, with revenue falling to Rs 56.21 crore and net profit to Rs 1.26 crore. The company has opted not to declare a dividend to conserve cash for growth. Additionally, the company faces governance observations regarding board composition and software audit trails, which are slated for discussion at the upcoming AGM on September 23, 2026.
Adeshwar Meditex Reports FY26 Financials and Governance Challenges
Revenue: Rs 56.21 crore (down from Rs 83.97 crore YoY).
Net Profit: Rs 1.26 crore (down from Rs 2.06 crore YoY).
Reader Takeaway: Contracting financials alongside governance gaps in board composition and audit trail software implementations require investor attention.
What just happened
Adeshwar Meditex Ltd has released its financial results for the fiscal year ended March 31, 2026. The company experienced a decline across key metrics, with total revenue dropping significantly to Rs 56.21 crore from Rs 83.97 crore in the previous year. Consequently, the net profit after tax fell to Rs 1.26 crore, compared to Rs 2.06 crore in FY 2024-25. The Board of Directors has decided not to recommend a dividend for the year, citing the need to conserve resources for future business operations.
Why this matters
The financial downturn reflects operational challenges within the company’s core segments. Beyond the numbers, the Secretarial Audit Report has identified two critical compliance issues: the absence of required audit trail facilities in accounting software and a failure to meet board composition standards under the Companies Act, 2013, due to an insufficient number of independent directors. These findings highlight potential governance risks that shareholders should note.
Corporate Action Details
The 19th Annual General Meeting is set for September 23, 2026, in Mumbai. Key agenda items include the formal adoption of financial statements and several board-level transitions. These include the re-appointment of Mr. Nagaraja Rao Abhinandan, the appointment of a new statutory auditor, M/s. Shankar Ramesh & Co. LLP, and the appointment of Mrs. Bhagyalaxmi Kavital as a Non-Executive Independent Director, a move intended to rectify the current board composition non-compliance.
What to track next
Investors should monitor the company's progress on implementing the required audit trail software and the successful onboarding of the new independent director. Further, management’s ability to stabilize revenue in the wound dressing and hygiene sectors remains a primary point of interest for long-term holders.